We recently compiled a list of the 10 Hottest Mid-Cap Stocks So Far in 2025. In this article, we are going to take a look at where Inari Medical, Inc. (NASDAQ:NARI) stands against the other mid-cap ...

Inari’s catalog includes the catheter-based FlowTriever and ClotTriever systems for mechanically removing blood clots in cases of pulmonary embolism and deep vein thrombosis, respectively.

VTE is a term for blood clots in the veins, which can lead to serious illness, disability, or death. Inari’s product portfolio complements Stryker’s Neurovascular business and includes ...

Inari Medical stock skyrocketed Monday afternoon and again Tuesday morning after a report that it was close to being acquired by Stryker proved to be true, with the companies announcing the deal after ...

The deal for Inari bolsters Stryker's efforts to build out its offerings to treat a condition called venous thromboembolism, where a blood clot forms in a vein, and other vascular diseases.

After the MedTech giant Stryker (NYSE:SYK) agreed to offer $4.9B in cash to acquire Inari Medical (NASDAQ:NARI), a maker of clot removal systems, shares of its rival Penumbra (NYSE:PEN ...

Inari’s portfolio of medical devices and accessories to treat venous thromboembolism (VTE), or blood clots in the veins, was highly attractive to Stryker, according to Inari Chief Executive Drew Hykes ...

1 Inari provides solutions for VTE clot removal without the use of thrombolytic drugs. “The acquisition of Inari expands Stryker's portfolio to provide life-saving solutions to patients who ...

Stryker reported goodwill and other impairments of $818 million related to the spine business in the fourth quarter.

Inari shareholders are getting a fair price relative ... risks and costs of thrombolytic therapy (drugs meant to break up clots) and a growing database on the safety and efficacy of mechanical ...